Evercore ISI Group Maintains Outperform on Crinetics Pharmaceuticals, Lowers Price Target to $88

Benzinga Newsdesk www.benzinga.com Negative 95.4%

Neg 95.4% Neu 0% Pos 0%

Evercore ISI Group analyst Maneka Mirchandaney maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform and lowers the price target from $89 to $88.